[{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apnimed Successfully Completes Phase 1 Study in Lead Program for Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II"},{"orgOrder":0,"company":"Apnimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data Presented at ATS Meeting Reinforces the Potential of an Oral Drug Combination Therapy for Obstructive Sleep Apnea","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Trigone Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trigone Pharma to Present Preclinical Data for TRG-100 in Interstitial Cystitis \/ Bladder Pain Syndrome at the AUA Conference","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000287
The in-vitro and animal data suggest that TRG-100 can safely be used for possible intravesical sustained release of Lidocaine and Oxybutynin in the treatment of BPS/IC.
Apnimed’s lead product candidate, AD109, targets the neurologic control and facilitates the activation of the upper airway dilator muscles to maintain an open airway during sleep.
In this healthy volunteer study, R-oxybutynin, a key component of AD109, demonstrated a favorable pharmacokinetic (PK) profile and was well tolerated with no adverse events related to the study drug.